(AOF) – Genomic Vision gained more than 37% to 0.016 euro after publishing a description of its share buyback program. Biotech announces that the maximum share of the capital whose redemption is authorized is equal to 10% of the number of shares making up the share capital on the day of the Meeting, the maximum purchase price is 5 euros per share and the amount maximum of the program will be 2 million euros. The duration of the program is 18 months from the General Meeting of June 29, 2023, i.e. until December 28, 2024.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.